These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 19021061)

  • 1. Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response.
    Houldsworth J; Petlakh M; Olshen AB; Chaganti RS
    Leuk Lymphoma; 2008 Nov; 49(11):2170-80. PubMed ID: 19021061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in Chinese population.
    Chen W; Wang H; Chen H; Liu S; Lu H; Kong D; Huang X; Kong Q; Lu Z
    Eur J Haematol; 2014; 92(5):407-12. PubMed ID: 24400911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-κB pathway.
    Ramachandiran S; Adon A; Guo X; Wang Y; Wang H; Chen Z; Kowalski J; Sunay UR; Young AN; Brown T; Mar JC; Du Y; Fu H; Mann KP; Natkunam Y; Boise LH; Saavedra HI; Lossos IS; Bernal-Mizrachi L
    Int J Cancer; 2015 May; 136(10):2341-51. PubMed ID: 25359525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.
    Marques SC; Ranjbar B; Laursen MB; Falgreen S; Bilgrau AE; Bødker JS; Jørgensen LK; Primo MN; Schmitz A; Ettrup MS; Johnsen HE; Bøgsted M; Mikkelsen JG; Dybkær K
    Exp Hematol; 2016 Apr; 44(4):238-46.e2. PubMed ID: 26854484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
    Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
    Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
    Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.
    Bu R; Hussain AR; Al-Obaisi KA; Ahmed M; Uddin S; Al-Kuraya KS
    Leuk Lymphoma; 2014 Feb; 55(2):415-24. PubMed ID: 23697845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma.
    Lv X; Feng L; Ge X; Lu K; Wang X
    J Exp Clin Cancer Res; 2016 Jul; 35(1):106. PubMed ID: 27364124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma.
    Eluard B; Nuan-Aliman S; Faumont N; Collares D; Bordereaux D; Montagne A; Martins I; Cagnard N; Caly M; Taoui O; Lordello L; Lehmann-Che J; Tesson B; Martinez-Climent JA; Copie-Bergman C; Haioun C; Tilly H; Bonsang B; Vincent-Salomon A; Jais JP; Jardin F; Leroy K; Maiuri MC; Kroemer G; Molina TJ; Feuillard J; Baud V
    Blood; 2022 Jan; 139(3):384-398. PubMed ID: 34232979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
    Lam LT; Davis RE; Pierce J; Hepperle M; Xu Y; Hottelet M; Nong Y; Wen D; Adams J; Dang L; Staudt LM
    Clin Cancer Res; 2005 Jan; 11(1):28-40. PubMed ID: 15671525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
    Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
    Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
    Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
    EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
    Peng W; Wu J; Feng J
    Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.
    Zhang M; Xu-Monette ZY; Li L; Manyam GC; Visco C; Tzankov A; Wang J; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Pham LV; Young KH
    Aging (Albany NY); 2016 Dec; 8(12):3321-3340. PubMed ID: 27941215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
    Wong KK; Gascoyne DM; Soilleux EJ; Lyne L; Spearman H; Roncador G; Pedersen LM; Møller MB; Green TM; Banham AH
    Oncotarget; 2016 Aug; 7(33):52940-52956. PubMed ID: 27224915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
    Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy.
    Li Q; Huang J; Ou Y; Li Y; Wu Y
    Immunotherapy; 2019 Mar; 11(4):265-272. PubMed ID: 30606076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of heme oxygenase-1 induced by constitutively activated NF-κB as a potential therapeutic target for activated B-cell-like diffuse large B-cell lymphoma.
    Huang J; Guo P; Ma D; Lin X; Fang Q; Wang J
    Int J Oncol; 2016 Jul; 49(1):253-64. PubMed ID: 27211510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP.
    Liu Y; Wang X; Ding N; Mi L; Ping L; Jin X; Li J; Xie Y; Ying Z; Liu W; Zhang C; Deng L; Song Y; Zhu J
    BMC Cancer; 2017 Nov; 17(1):743. PubMed ID: 29126407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTEN tumor suppressor plays less prognostic role than P53 tumor suppressor in diffuse large B-cell lymphoma.
    Liu YY; Yao SN; Zhao Y; Yao ZH; Ma J; Xia QX; Fu K; Yang SJ
    Leuk Lymphoma; 2010 Sep; 51(9):1692-8. PubMed ID: 20807096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.